SG11202111330XA - Engineered ph-dependent anti-cd3 antibodies, and methods for their generation and use - Google Patents

Engineered ph-dependent anti-cd3 antibodies, and methods for their generation and use

Info

Publication number
SG11202111330XA
SG11202111330XA SG11202111330XA SG11202111330XA SG11202111330XA SG 11202111330X A SG11202111330X A SG 11202111330XA SG 11202111330X A SG11202111330X A SG 11202111330XA SG 11202111330X A SG11202111330X A SG 11202111330XA SG 11202111330X A SG11202111330X A SG 11202111330XA
Authority
SG
Singapore
Prior art keywords
engineered
antibodies
generation
methods
dependent anti
Prior art date
Application number
SG11202111330XA
Inventor
James Geoghegan
Bianka Prinz
Robert Pejchal
Original Assignee
Adimab Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adimab Llc filed Critical Adimab Llc
Publication of SG11202111330XA publication Critical patent/SG11202111330XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11202111330XA 2019-06-07 2020-06-08 Engineered ph-dependent anti-cd3 antibodies, and methods for their generation and use SG11202111330XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962858968P 2019-06-07 2019-06-07
PCT/US2020/036657 WO2020247932A1 (en) 2019-06-07 2020-06-08 Engineered ph-dependent anti-cd3 antibodies, and methods for their generation and use

Publications (1)

Publication Number Publication Date
SG11202111330XA true SG11202111330XA (en) 2021-12-30

Family

ID=73652648

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111330XA SG11202111330XA (en) 2019-06-07 2020-06-08 Engineered ph-dependent anti-cd3 antibodies, and methods for their generation and use

Country Status (12)

Country Link
US (1) US20220380463A1 (en)
EP (1) EP3980465A4 (en)
JP (1) JP2022536246A (en)
KR (1) KR20220035368A (en)
CN (1) CN114144437A (en)
AU (1) AU2020287384A1 (en)
BR (1) BR112021020426A2 (en)
CA (1) CA3141914A1 (en)
IL (1) IL288620A (en)
MX (1) MX2021014966A (en)
SG (1) SG11202111330XA (en)
WO (1) WO2020247932A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202002248TA (en) 2017-10-02 2020-04-29 Visterra Inc Antibody molecules to cd138 and uses thereof
EP4355785A1 (en) * 2021-06-17 2024-04-24 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
CA3226397A1 (en) 2021-07-22 2023-01-26 Ignacio Moraga GONZALEZ Therapeutic muteins
WO2023097254A1 (en) * 2021-11-24 2023-06-01 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof
CN117924510B (en) * 2024-03-21 2024-06-04 北京星基贝勤生物科技有限公司 Bispecific antibody targeting EGFR and AXL, and drug conjugate and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0511782B8 (en) * 2004-06-03 2021-05-25 Novimmune Sa anti-cd3 antibodies, use and method of production thereof, pharmaceutical composition, isolated nucleic acid molecule and vector
TWI564021B (en) * 2008-04-11 2017-01-01 Chugai Pharmaceutical Co Ltd Repeated binding of antigen to antigen binding molecules
JOP20200236A1 (en) * 2012-09-21 2017-06-16 Regeneron Pharma Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
EP4257613A3 (en) * 2016-06-14 2023-12-13 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
WO2018075974A2 (en) * 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
CN108264566B (en) * 2016-12-30 2021-05-14 惠和生物技术(上海)有限公司 Bispecific molecule fusing anti-CD3 antibody structural domain and T cell positive co-stimulatory molecule ligand and application thereof
WO2018208864A1 (en) * 2017-05-08 2018-11-15 Adimab, Llc Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use

Also Published As

Publication number Publication date
EP3980465A4 (en) 2023-11-01
US20220380463A1 (en) 2022-12-01
KR20220035368A (en) 2022-03-22
AU2020287384A1 (en) 2021-11-11
EP3980465A1 (en) 2022-04-13
JP2022536246A (en) 2022-08-15
WO2020247932A1 (en) 2020-12-10
CN114144437A (en) 2022-03-04
IL288620A (en) 2022-02-01
MX2021014966A (en) 2022-04-11
BR112021020426A2 (en) 2022-03-08
CA3141914A1 (en) 2020-12-10

Similar Documents

Publication Publication Date Title
IL288620A (en) Engineered ph-dependent anti-cd3 antibodies, and methods for their generation and use
SG10201912494TA (en) Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use
PH12018500295A1 (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
IL253569A0 (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
SG11202011270QA (en) Anti-cd3 antibodies and uses thereof
AU2016210068A1 (en) Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123
IL278924A (en) Antibodies specific for gucy2c and uses thereof
PH12019502087A1 (en) Anti-par2 antibodies and uses thereof
EP4249515A3 (en) Humanized or chimeric cd3 antibodies
EP3411069A4 (en) Humanized anti-cd3 antibodies, conjugates and uses thereof
IL291299A (en) Anti-tnfr2 antibodies, composotions comprising same and uses thereof
SG11202103104RA (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
IL288607A (en) High affinity anti-cd3 antibodies, and methods for their generation and use
MX2014000531A (en) Methods and compositions for treating asthma using anti-il-13 antibodies.
IL276746A (en) Kir3dl3 as an hhla2 receptor, anti-hhla2 antibodies, and uses thereof
IL278926A (en) Antibodies specific for cd3 and uses thereof
EP3395834A4 (en) Tpbg antibody and preparation method therefor, conjugate and use thereof
ZA202003858B (en) Monoclonal antibodies and methods for using same
IL311039A (en) Anti-cd3 antibodies
IL272733A (en) Monoclonal antibodies against pathological alpha-synuclein, and methods using same
EP3722311A4 (en) Anti-human il6 monoclonal antibodies, preparation method therefor and use thereof
IL289158A (en) Anti-cd123 antibodies, anti-cd123 chimeric antigen receptors and anti-cd123 chimeric antigen receptors t cells
GB201918103D0 (en) Epitopes and antibodies
GB201918104D0 (en) Epitopes and antibodies
ZA202210284B (en) Anti-trem1 antibodies and related methods